Why Immunotherapy Fails in Multiple Myeloma

被引:6
|
作者
Rodriguez-Lobato, Luis Gerardo [1 ,2 ]
Oliver-Caldes, Aina [1 ,2 ]
Moreno, David F. [1 ,2 ]
de Larrea, Carlos Fernandez [1 ,2 ]
Blade, Joan [1 ,2 ]
机构
[1] Hosp Clin Barcelona, Dept Hematol, Amyloidosis & Multiple Myeloma Unit, Barcelona 08036, Spain
[2] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona 08036, Spain
来源
HEMATO | 2021年 / 2卷 / 01期
基金
欧盟地平线“2020”;
关键词
multiple myeloma; immunotherapy; daratumumab; BCMA; bi-specific T cell engagers; chimeric antigen receptor; relapse; cytokine-release syndrome; CHIMERIC-ANTIGEN-RECEPTOR; CAR-T-CELLS; IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT; FIBROBLAST ACTIVATION PROTEIN; MARROW STROMAL CELLS; B-CELL; ANTITUMOR-ACTIVITY; MATURATION ANTIGEN; OPEN-LABEL; CANCER-IMMUNOTHERAPY;
D O I
10.3390/hemato2010001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma remains an incurable disease despite great advances in its therapeutic landscape. Increasing evidence supports the belief that immune dysfunction plays an important role in the disease pathogenesis, progression, and drug resistance. Recent efforts have focused on harnessing the immune system to exert anti-myeloma effects with encouraging outcomes. First-in-class anti-CD38 monoclonal antibody, daratumumab, now forms part of standard treatment regimens in relapsed and refractory settings and is shifting to front-line treatments. However, a non-negligible number of patients will progress and be triple refractory from the first line of treatment. Antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptors (CAR) are being developed in a heavily pretreated setting with outstanding results. Belantamab mafodotin-blmf has already received approval and other anti-B-cell maturation antigen (BCMA) therapies (CARs and bispecific antibodies are expected to be integrated in therapeutic options against myeloma soon. Nonetheless, immunotherapy faces different challenges in terms of efficacy and safety, and manufacturing and economic drawbacks associated with such a line of therapy pose additional obstacles to broadening its use. In this review, we described the most important clinical data on immunotherapeutic agents, delineated the limitations that lie in immunotherapy, and provided potential insights to overcome such issues.
引用
收藏
页码:1 / 42
页数:42
相关论文
共 50 条
  • [41] Targeting RANKL for Immunotherapy of Multiple Myeloma
    Schmiedel, Benjamin J.
    Grosse-Hovest, Ludger
    Bugl, Stefanie
    Kopp, Hans-Georg
    Wirths, Stefan
    Pichler, Bernd J.
    Azuma, Miyuki
    Schneider, Pascal
    Kanz, Lothar
    Jung, Gundram
    Salih, Helmut R.
    BLOOD, 2011, 118 (21) : 1253 - 1253
  • [42] Immunotherapy Strategies Against Multiple Myeloma
    Ma, Jing
    Li, Qian
    Yu, Zhen
    Cao, Zeng
    Liu, Su
    Chen, Lin
    Li, Han
    Gao, Shuang
    Yan, Tinghui
    Wang, Yafei
    Liu, Qiang
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2017, 16 (06) : 717 - 726
  • [43] Management and place of immunotherapy in multiple myeloma
    Leleu, Xavier
    HEMATOLOGIE, 2020, 26 : 3 - 3
  • [44] Facts and Hopes in Multiple Myeloma Immunotherapy
    Sperling, Adam S.
    Anderson, Kenneth C.
    CLINICAL CANCER RESEARCH, 2021, 27 (16) : 4468 - 4477
  • [45] Immunotherapy in multiple myeloma - possibility or probability?
    Harrison, SJ
    Cook, G
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (03) : 344 - 362
  • [46] Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma
    Chang, Andres
    Nasti, Tahseen H.
    Khan, Mohammad K.
    Parashar, Susmita
    Kaufman, Jonathan L.
    Boise, Lawrence H.
    Lonial, Sagar
    Ahmed, Rafi
    Nooka, Ajay K.
    JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (09) : 561 - +
  • [47] Novel immunotherapy strategies in multiple myeloma
    Munshi, N. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 46 - 47
  • [48] Gene Editing Provides Clues to Why Cancer Immunotherapy Often Fails
    Hampton, Tracy
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (17): : 1641 - 1642
  • [49] International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
    Costa, Luciano J.
    Banerjee, Rahul
    Mian, Hira
    Weisel, Katja
    Bal, Susan
    Derman, Benjamin A.
    Htut, Maung M.
    Nagarajan, Chandramouli
    Rodriguez, Cesar
    Richter, Joshua
    Frigault, Matthew J.
    Ye, Jing C.
    van de Donk, Niels W. C. J.
    Voorhees, Peter M.
    Puliafito, Benjamin
    Bahlis, Nizar
    Popat, Rakesh
    Chng, Wee Joo
    Ho, P. Joy
    Kaur, Gurbakhash
    Kapoor, Prashant
    Du, Juan
    Schjesvold, Fredrik
    Berdeja, Jesus
    Einsele, Hermann
    Cohen, Adam D.
    Mikhael, Joseph
    Biru, Yelak
    Rajkumar, S. Vincent
    Lin, Yi
    Martin, Thomas G.
    Chari, Ajai
    LEUKEMIA, 2025, 39 (03) : 543 - 554
  • [50] New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
    Neri, Paola
    Bahlis, Nizar J.
    Lonial, Sagar
    CLINICAL CANCER RESEARCH, 2016, 22 (24) : 5959 - 5965